Paolo Tarantino: Rebecca Shatsky presents the Dato/durva module of I-SPY2.2

Paolo Tarantino shared on X/Twitter:

“Rebecca Shatsky presents the Dato/durva module of I-SPY2.2. Neoadjuvant Dato-DXd/durva showed promising pCR rates, particularly in TNBC (44%) and HER2-Immune+ subtype (65%), where it met the graduation threshold. Key tox: nausea, stomatitis, rash, alopecia, ocular tox.”

Source: Paolo Tarantino/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer.
Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.

Rebecca Shatsky is an Associate Professor at UC San Diego Health, Breast Medical Oncology Co-Team Leader, Scientific Director of the Inflammatory and Triple Negative Breast Cancer Program.

She is a member of the NCCN guideline panel for Genetic/High-Risk Assessment of Breast, Ovarian and Pancreatic Cancer and the panel for the treatment of Cancer-Associated Pain. Her work has been published in JAMA Oncology, Cancer Cell and Molecular Cancer Therapeutics, among others. Dr. Shatsky is a member of the American Association for Cancer Research and the American Society of Clinical Oncology.